Two of the best known are tetrahydrocannabinol (THC) and CBD. Although THC is the cannabinoid that causes the “high feeling” that many people associate with cannabis, research suggests that CBD may help relieve inflammation, among other things. Perhaps the most popular high-CBD strain in North America, Harlequin treats anxiety, chronic pain, inflammation, PMS and cramps, among others. It is often described as producing lucid and uplifting effects.
THC is responsible for that “high” people get from marijuana, which can also play a role in pain relief. CBD doesn't usually cause an intoxicating sensation, but research suggests that it may also help relieve arthritis symptoms. Chronic inflammation affects 43 million Americans each year. It's a painful condition that has left many people with constant discomfort.
Fortunately, the herb's therapeutic properties can offer some relief for those still seeking relief. Premium manufacturer Rare Cannabinoid Company uses this hemp purified CBG to create 500 mg CBG oil extracts and one-to-one CBG CBD blends that combine CBG with rare full-spectrum Hawaiian CBD. CBD doesn't cause a high, although it does interact with pain receptors in the brain to exert analgesic and anti-inflammatory effects. Until recently, there was no consensus on the role of cannabinoids in the treatment of chronic pain.
Researchers suggest that cannabis or cannabinoids may be effective in treating some types of chronic pain, including neuropathy (nerve pain). Although CBD as monotherapy in the treatment of pain has not been clinically evaluated, its anti-inflammatory (Ko et al. Interestingly, one of the few drugs containing cannabinoids was approved as a treatment for neuropathic pain in patients with multiple sclerosis. Experiments with animal models of cancer pain support the use of cannabinoids in the treatment of cancer pain in humans.
Clinical data also indicate that cannabinoids can only modestly reduce chronic pain, like all drugs currently available for the treatment of chronic pain in humans (Romero-Sandoval et al. This study shows that oral cannabinoids are modestly effective in reducing chronic neuropathic pain and that this requires a minimum of 2 weeks of treatment. The two main cannabinoids, THC and CBD, have anti-inflammatory properties and both fight pain in different ways, which is one of the reasons why the best strains for pain often contain a healthy proportion of both. All of these receptors have been shown to represent potentially attractive targets for the therapeutic use of cannabinoids in the treatment of pain.
Cannabinoids and cannabis are old drugs, but they are now a promising new therapeutic strategy for the treatment of pain. The authors concluded that there is insufficient evidence to recommend the use of cannabinoids for the treatment of pain in patients with rheumatic diseases. At the same time, the Special Interest Group on Neuropathic Pain of the International Association for the Study of Pain provided “a weak recommendation against the use of cannabinoids in neuropathic pain, mainly due to negative outcomes, potential misuse, abuse, diversion and long-term mental health risks term particularly in susceptible patients (Finnerup et al.
